- Details
- Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. Findings reveal most patients experience mild symptoms post-surgery, with a significa...
|
- Details
- Ruchika Talwar hosts Hannah Kay and Marc Bjurlin to unravel their study on the sparse reporting of smoking status in bladder cancer trials. Their research, "Clearing the Smoke," highlights a concerning discrepancy: only 41.2% of bladder cancer trials over the past decade reported participants' smoking status, starkly contrasting with higher reporting rates in lung cancer trials. This gap suggests...
|
- Details
- Sam Chang engages in an conversation with Elizabeth Koehne who delves into her research, AIM HIGH: DNA Methyltransferase Inhibition and Immune Stimulation in Bladder Cancer. The project explores the potential of making bladder cancer more susceptible to immunotherapy by reversing epigenetic mechanisms, like DNA methylation and chromatin remodeling, that the cancer uses to evade the immune system....
|
- Details
- Sam Chang leads a discussion with Ashish Kamat and Matt Galsky on their co-authored article, focusing on new trial parameters for urothelial carcinoma. This collaboration, involving SITC, IBCG, FDA stakeholders, and patient advocates, responds to the urgent need for detailed clinical trial guidelines due to the dynamic landscape of bladder cancer treatment. The dialogue highlights the transition t...
|
- Details
- Sam Chang hosts a conversation with Mark Preston discussing innovative chemotherapy combinations for non-muscle invasive bladder cancer. Drawing inspiration from Dr. Mike O'Donnell's work with gemcitabine and docetaxel, Dr. Preston's team sought to replicate these promising results. Their multi-institutional retrospective analysis examined over 100 patients treated with this regimen after BCG ther...
|
- Details
- Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in th...
|
- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Ashish Kamat converses with Akshay Sood about the challenging diagnosis and management of non-metastatic plasmacytoid bladder cancer. Dr. Sood elaborates on his comprehensive study published in the Journal of Urology. He highlights the rarity and lethal nature of the plasmacytoid variant, which represents approximately 1% of muscle-invasive bladder cancers. Through a retrospective analysis of 56 p...
|
- Details
- Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...
|
- Details
- Sam Chang engages with Roger Li to delve into the TAR-210 study, focusing on bladder-based intravesical therapy targeting FGFR3 in non-muscle invasive bladder cancer (NMIBC) patients. Dr. Li shares insights from the multi-site international study, highlighting the efficacy of Erdafitinib, particularly in patients with FGFR alterations. Despite the challenges with oral Erdafitinib's toxicity, the i...
|